Related Experiment Videos
[Clinical efficacy and safety of norfloxacin tablets in pediatrics]
Insights
Norfloxacin tablets demonstrated high therapeutic effectiveness, with a 93% efficacy rate in treating bacterial infections in children. This study found norfloxacin to be a safe and usable option for pediatric patients.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Clinical microbiology
Context:
- Bacterial infections in children require effective and safe treatment options.
- Norfloxacin is a fluoroquinolone antibiotic with broad-spectrum activity.
- Evaluating the pediatric utility of established antibiotics is crucial for evidence-based practice.
Purpose:
- To evaluate the therapeutic effectiveness and safety of norfloxacin tablets in pediatric patients.
- To determine the efficacy rate of norfloxacin in treating common childhood bacterial infections.
- To identify and document any adverse events associated with norfloxacin use in children.
Summary:
- A clinical study involved 14 children with urinary tract infections or acute bronchitis, treated with norfloxacin at doses of 1.7–5.4 mg/kg b.i.d. or t.i.d. for 3–15 days.
- An overall efficacy rate of 93% was achieved, with 8 patients showing an "excellent" response and 5 showing a "good" response.
- Adverse events were minimal, including light-headedness and vomiting in two cases, with minor laboratory abnormalities (eosinophilia, elevated GOT) in others.
Impact:
- Norfloxacin is confirmed as a usable antimicrobial agent for pediatric bacterial infections.
- The findings support the inclusion of norfloxacin in the pediatric pharmacopeia for specific indications.
- This study contributes to the evidence base for antibiotic use in pediatric populations.
Abstract:
We have evaluated norfloxacin (NFLX) tablets for therapeutic effectiveness and safety in children. The results are summarized as follows. 1. A clinical study was performed on 14 children with infections, including 12 with urinary tract infections and 2 with acute bronchitis. Doses ranging from 1.7 to 5.4 mg/kg body weight were given b.i.d. or t.i.d.. Lengths of treatment ranged from 3 to 15 days. The therapeutic responses were considered "excellent" in 8 and "good" in 5, with an efficacy rate of 93%. 2. Side effects were observed in 2 cases, one with light-headed feeling and one with vomiting. In clinical laboratory tests, eosinophilia was found in 2 cases and GOT was slightly elevated in 1 case. It has been concluded that NFLX is a usable drug for the treatment of bacterial infections in children.